Lenalidomide plus R-DA-EPOCH for MYC-rearranged lymphoma
Part of Blood & lymphatic, Cancer clinical trials.
This early-phase study tests whether lenalidomide combined with R-DA-EPOCH can treat untreated diffuse large B-cell lymphoma (DLBCL) that has a MYC rearrangement. It may help control the lymphoma, but it’s also designed to find the safest and most effective dosing.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have confirmed DLBCL with a MYC rearrangement, not other similar lymphoma types like PCNSL or HIV-related lymphoma
- You should be 18 to 60 years old, and well enough to do daily activities (ECOG 0–2)
- Your doctor must expect you can live at least 12 weeks, and you must have measurable or evaluable tumors (about 1.5 cm or larger)
- You must agree to sign informed consent and attend frequent study visits as scheduled
- You cannot have had any prior anti-cancer treatment for this lymphoma
- You must have adequate heart, liver, kidney, blood counts, and no recent serious blood clots or nervous-system involvement
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether the combination of tafasitamab and lenalidomide can work better and be safe for people whose large B-cell lymphoma has returned or did not respond. It may help by targeting lymphoma cells and supporting immune activity, while monitoring side effects closely.
This trial tests a new combination of drugs (tafasitamab + lenalidomide + gemcitabine + oxaliplatin) against a standard combination (rituximab + gemcitabine + oxaliplatin) for people with DLBCL that has returned or stopped responding to prior therapy. The goal is to see if the new combination works better.
This study tests combining the drug lenalidomide with a standard chemotherapy regimen (G-CHOP) for people newly diagnosed with a specific type of lymphoma that has both aggressive and slow-growing parts. The goal is to see if this combination works better than standard treatment alone.
This study tests a new drug (IMM0306) combined with lenalidomide, compared to a placebo with lenalidomide, for people with follicular lymphoma that has come back or not responded to treatment. The goal is to see if adding IMM0306 helps control the cancer better.
This trial tests a combination of two drugs, epcoritamab and lenalidomide, for patients with a rare type of large B-cell lymphoma linked to a weakened immune system. It is for people whose lymphoma did not improve or returned after standard treatments, and who cannot get CAR-T therapy.
This trial tests a combination of radiation therapy, lenalidomide, and glofitamab for people with a type of lymphoma called DLBCL that has not responded to or has returned after initial treatment. The goal is to see if this combination can help when other treatments have failed.
Hear when a new DLBCL trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.